[en] OBJECTIVES: The primary objective was to evaluate the safety and local tolerance of a topical 2% (w/w) cidofovir gel, applied directly to the cervices of women with high-grade cervical intraepithelial neoplasia (CIN 2+). The secondary objective was to evaluate the pharmacokinetics of cidofovir during the treatment. MATERIALS AND METHODS: Nine women with CIN 2+, were treated with a course of 3 g of cidofovir gel, applied locally once per week for 3 weeks in total (9 g). The treatment was administered in a cervical cap, applied to the cervix for 5 or 10 hours (n = 6 and 3 patients, respectively). Follow-up included a structured questionnaire, a gynecological examination, blood analysis for hematology, C-reactive protein (CRP), and renal function assessment plus pharmacokinetic analyses of cidofovir after each treatment and at the end of the full course. RESULTS: No clinically significant hematological/biochemical abnormalities or serious adverse events (SAE) were reported, although 6 mild to moderate adverse events (AE) occurred in relation to the study drug: 1 flu-like syndrome and 5 local AEs. Plasma concentrations of cidofovir were very low (mean Cmax of 103.0 and 99.2 ng/mL after 5 and 10 hours of exposure, respectively). CONCLUSION: Cidofovir, directly applied on CIN 2+, is reasonably well tolerated and the systemic exposure following topical application is much lower than that seen with intravenous administration, at the approved dose..
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Bossens, Michel
Jost, Maud
Van Pachterbeke, Catherine
De Maertelaer, Viviane
Simon, Philippe
Frankenne, Francis
Hubert, Philippe ; Université de Liège - ULiège > Département de pharmacie > Chimie analytique
Evrard, Brigitte ; Université de Liège - ULiège > Département de pharmacie > Pharmacie galénique
Snoeck, Robert
Language :
English
Title :
Safety and tolerance of cidofovir as a 2% gel for local application in high-grade cervical intraepithelial neoplasia: A phase 1 investigation.
Publication date :
2018
Journal title :
International Journal of Clinical Pharmacology and Therapeutics
Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol. 2008; 168: 123-137. CrossRef PubMed
Simoens C, Goffin F, Simon P, Barlow P, Antoine J, Foidart JM, Arbyn M. Adverse obstetrical outcomes after treatment of precancerous cervical lesions: a Belgian multicentre study. BJOG. 2012; 119: 1247-1255. CrossRef PubMed
Lalezari JP, Holland GN, Kramer F, McKinley GF, Kemper CA, Ives DV, Nelson R, Hardy WD, Kuppermann BD, Northfelt DW, Youle M, Johnson M, Lewis RA, Weinberg DV, Simon GL, Wolitz RA, Ruby AE, Stagg RJ, Jaffe HS. Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 17: 339-344. CrossRef PubMed
Snoeck R, Noel JC, Muller C, De Clercq E, Bossens M. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III). J Med Virol. 2000; 60: 205-209. CrossRef PubMed
Snoeck R, Bossens M, Parent D, Delaere B, Degreef H, Van Ranst M, Noël JC, Wulfsohn MS, Rooney JF, Jaffe HS, De Clercq E. Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clin Infect Dis. 2001; 33: 597-602. CrossRef PubMed
Stragier I, Snoeck R, De Clercq E, Van Den Oord JJ, Van Ranst M, De Greef H. Local treatment of HPV-induced skin lesions by Cidofovir. J Med Virol. 2002; 67: 241-245. CrossRef PubMed
De Schutter T, Andrei G, Topalis D, Naesens L, Snoeck R. Cidofovir selectivity is based on the different response of normal and cancer cells to DNA damage. BMC Med Genomics. 2013; 6: 18. CrossRef PubMed
Clamp PJ, Saunders MW. Systematic review of intralesional cidofovir dosing regimens in the treatment of recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol. 2013; 77: 323-328. CrossRef PubMed
Stier EA, Goldstone SE, Einstein MH, Jay N, Berry JM, Wilkin T, Lee JY, Darragh TM, Da Costa M, Panther L, Aboulafia D, Palefsky JM. Safety and efficacy of topical cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women. AIDS. 2013; 27: 545-551. CrossRef PubMed
Van Pachterbeke C, Bucella D, Rozenberg S, Manigart Y, Gilles C, Larsimont D, Vanden Houte K, Reynders M, Snoeck R, Bossens M. Topical treatment of CIN 2+ by cidofovir: results of a phase II, double-blind, prospective, placebo-controlled study. Gynecol Oncol. 2009; 115: 69-74. CrossRef PubMed
Tristram A, Hurt CN, Madden T, Powell N, Man S, Hibbitts S, Dutton P, Jones S, Nordin AJ, Naik R, Fiander A, Griffiths G. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT3VIN): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2014; 15: 1361-1368. Cross-Ref PubMed
Cundy KC, Lynch G, Lee WA. Bioavailability and metabolism of cidofovir following topical administration to rabbits. Antiviral Res. 1997; 35: 113-122. CrossRef PubMed
Bienvenu B, Martinez F, Devergie A, Rybojad M, Rivet J, Bellenger P, Morel P, Gluckman E, Lebbé C. Topical use of cidofovir induced acute renal failure. Transplantation. 2002; 73: 661-662. CrossRef PubMed
Saunders IM, Lahoti A, Chemaly RF, Trevino C, Westmoreland M, Hosing C. Topical cidofovirinduced acute kidney injury in two severely immunocompromised patients with refractory multidrug-resistant herpes simplex virus infections. J Oncol Pharm Pract. 2016; 22: 325-331. CrossRef PubMed
Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet. 1999; 36: 127-143. Cross-Ref PubMed
Lecomte F, Hubert C, Demarche S, De Bleye C, Dispas A, Jost M, Frankenne F, Ceccato A, Rozet E, Hubert P. Comparison of the quantitative performances and measurement uncertainty estimates obtained during method validation versus routine applications of a novel hydrophilic interaction chromatography method for the determination of cidofovir in human plasma. J Pharm Biomed Anal. 2012; 57: 153-165. CrossRef PubMed
Sendagorta E, Bernardino JI, Álvarez-Gallego M, Feíto M, Feltes R, Beato MJ, Pérez-Molina JA, Yllescas M, Díaz-Almirón M, Arribas JR, González-García J, Herranz P; CIDAN127412 GESIDA Study Group. Topical cidofovir to treat high-grade anal intraepithelial neoplasia in HIVinfected patients: a pilot clinical trial. AIDS. 2016; 30: 75-82. PubMed
Wan J, Vittorio CC, Abuabara K, Kurd SK, Musiek A, Steinemann JM, Gelfand JM. A randomized, double-blind, placebo-controlled proof of concept trial of topical cidofovir, 1% and 3%, for the prevention of beard hair growth in men. Arch Dermatol. 2012; 148: 257-259. CrossRef PubMed
Sacks SL, Shafran SD, Diaz-Mitoma F, Trottier S, Sibbald RG, Hughes A, Safrin S, Rudy J, McGuire B, Jaffe HS. A multicenter phase I/II dose escalation study of single-dose cidofovir gel for treatment of recurrent genital herpes. Antimicrob Agents Chemother. 1998; 42: 2996-2999. PubMed
Cundy KC, Petty BG, Flaherty J, Fisher PE, Polis MA, Wachsman M, Lietman PS, Lalezari JP, Hitchcock MJ, Jaffe HS. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 1995; 39: 1247-1252. CrossRef PubMed